Company news

Anavex Life Sciences Corp. news in 2026

Anavex Life Sciences Corp.'s news releases, calls and decks from 2026, newest first.

View company

Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors

November 3, 2026

Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies

October 20, 2026

Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome

October 15, 2026

PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences

September 18, 2026

Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change

September 17, 2026

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees

September 14, 2026

PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign

September 10, 2026

Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4: 00 PM ET

September 8, 2026

Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement

September 2, 2026

PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.’s 2026 Annual Meeting

September 1, 2026

Amendment to Annual Report (Form 10-K/A)

August 28, 2026

Anavex Life Sciences: Fiscal Q3 Earnings Snapshot

August 25, 2026

Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update

August 25, 2026

Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees

August 17, 2026

Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders

August 11, 2026

Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

August 3, 2026

Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

July 30, 2026

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

May 22, 2026

Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

May 6, 2026

Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease

April 13, 2026

Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

April 7, 2026

Anavex Life Sciences Provides Comprehensive Regulatory Update

March 29, 2026

Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease

March 22, 2026

New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease

March 20, 2026

Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference

March 17, 2026

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

March 3, 2026

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

February 25, 2026

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

February 23, 2026

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

February 9, 2026

Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

February 3, 2026

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

January 13, 2026

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

January 8, 2026

Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program

January 6, 2026

Calls in 2026

Decks in 2026